Bauer Michael, Whybrow Peter C, Angst Jules, Versiani Marcio, Möller Hans-Jürgen
University of California Los Angeles (UCLA), Neuropsychiatric Institute & Hospital, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA.
World J Biol Psychiatry. 2002 Apr;3(2):69-86. doi: 10.3109/15622970209150605.
These practice guidelines for the biological treatment of unipolar depressive disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal for developing these guidelines was to systematically review all available evidence pertaining to the treatment of the complete spectrum of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating patients with these conditions. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for depressive disorders, as well as from meta-analyses and reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into four levels of evidence (A-D). The first part of these WFSBP guidelines on unipolar depressive disorders covered the acute and continuation treatment of major depressive disorder (Bauer et al 2002). This second part of the guidelines covers the management of the maintenance-phase treatment of major depressive disorder, as well as the treatment of chronic and subthreshold depressive disorders (dysthymic disorder, double depression, minor depressive disorder and recurrent brief depression). These guidelines are primarily concerned with the biological treatment (including antidepressants, lithium, other psychopharmacological and hormonal medications, and electroconvulsive therapy) of young adults and also, albeit to a lesser extent, children, adolescents and older adults.
这些关于单相抑郁症生物治疗的实践指南由国际生物精神病学学会世界联合会（WFSBP）的一个特别工作组制定。制定这些指南的目的是系统地回顾与单相抑郁症全谱治疗相关的所有现有证据，并根据现有证据提出一系列具有临床和科学意义的实践建议。这些指南供所有诊治患有这些疾病患者的医生使用。用于制定这些指南的数据主要取自各国关于抑郁症的治疗指南和专家小组，以及通过检索MEDLINE数据库和Cochrane图书馆确定的关于抗抑郁药物和其他生物治疗干预措施疗效的荟萃分析和综述。对所确定的文献就其疗效证据的强度进行了评估，然后分为四个证据级别（A - D）。WFSBP关于单相抑郁症的这些指南的第一部分涵盖了重度抑郁症的急性和持续治疗（Bauer等人，2002年）。本指南的第二部分涵盖重度抑郁症维持期治疗的管理，以及慢性和亚阈值抑郁症（恶劣心境障碍、双重抑郁症、轻度抑郁症和复发性短暂抑郁症）的治疗。这些指南主要关注年轻人的生物治疗（包括抗抑郁药、锂盐、其他精神药物和激素药物以及电休克治疗），在较小程度上也关注儿童、青少年和老年人。
Zotero 插件